Catalyst Pharmaceuticals Faces $200M Revenue Loss as FIRDAPSE Patent Expires in 2035
FIRDAPSE patent protection ends February 2035, exposing Catalyst Pharmaceuticals to generic competition that will likely eliminate 70-80% of the drug's revenue within three years. The patent cliff threatens a revenue stream currently generating over $250 million annually for the rare disease treatment.
ViaNews Editorial Team (Finance)•